静脉注射免疫球蛋白在特发性炎性肌病中作用的批判性综述
该综述检索Medline和PubMed至2016年7月,评估静脉注射免疫球蛋白(IVIg)在特发性炎性肌病(IIM)中的治疗证据。3项随机对照试验支持IVIg用于皮肌炎和多肌炎难治性、复发性或激素依赖性疾病及老年皮肌炎一线治疗,其他适应症仅有无对照证据。结论认为需更高质量对照证据指导治疗决策。
要点
- 3项RCT支持IVIg用于皮肌炎和多肌炎难治、复发或激素依赖及老年皮肌炎一线治疗
- 其他适应症仅有无对照证据支持
- 现有研究多为开放、无对照或回顾性设计,样本小、随访短、结局指标非标准化
核心结论
- IVIg在IIM中的疗效仅由3项RCT支持,其他适应症证据有限,亟需更高质量对照研究指导治疗决策。
研究设计与样本
- 检索Medline(Ovid)和PubMed从建库至2016年7月,纳入原始研究和综述全文,并手工检索参考文献,数据定性总结并以表格呈现。
主要发现
- 3项RCT涉及皮肌炎和多肌炎受试者,支持IVIg用于难治性、复发性或激素依赖性疾病,以及老年皮肌炎患者的一线治疗。
- 其他IVIg适应症仅有无对照证据支持。
- 研究局限性包括开放、无对照或回顾性设计,样本小且经过选择,随访短期,以及临时定义的结局指标。
临床怎么用
- 对于难治性、复发性或激素依赖性皮肌炎和多肌炎,以及老年皮肌炎患者,可考虑IVIg治疗。
- 其他适应症使用IVIg需谨慎,应基于无对照证据并个体化决策。
局限性
- 现有证据多为开放、无对照或回顾性研究,样本量小且选择偏倚,随访时间短,结局指标非标准化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this review was to summarize key findings from the literature concerning the therapeutic role of intravenous immunoglobulins (IVIg) in idiopathic inflammatory myopathies (IIM), dissecting the evidence according to disease subtype and treatment indication, and to review the evidence relating to the mechanism of action of IVIg in IIM to ascertain rationale for continued research. METHODS: Medline (Ovid) and Pubmed databases were searched from inception to July 2016 using relevant keywords. Original and review articles were retrieved for full-text review. Bibliographies of selected articles were also hand-searched for additional references. Data were summarized qualitatively and in tabular form. RESULTS: The efficacy of IVIg in IIM is supported by 3 randomized controlled trials, involving dermatomyositis and polymyositis subjects, in refractory, relapsed, or steroid-dependent disease, as well as part of first-line therapy in elderly dermatomyositis subjects. Other indications for IVIg are supported by uncontrolled evidence only. Limitations of studies include open, uncontrolled or retrospective study designs, small and selected samples, short-term follow-up and ad hoc outcome measures. Despite the limited evidence, there is strong biological plausibility for the role of IVIg in IIM. CONCLUSION: Robust, controlled evidence to support the use of IVIg using validated outcome measures is urgently required to guide therapeutic decision-making and maximize outcomes in IIM.
引用
- Anh-Tu Hoa S, Hudson M. Critical review of the role of intravenous immunoglobulins in idiopathic inflammatory myopathies. Semin Arthritis Rheum. 2016. PMID: 27908534. doi:10.1016/j.semarthrit.2016.07.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。